US EditionPublished • loading... • Updated
Ultragenyx unwraps data that may be central to its gene therapy resubmission
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Ultragenyx unwraps data that may be central to its gene therapy resubmission
Ultragenyx outlined new data on Tuesday that it hopes will convince the FDA to approve its recently resubmitted rare disease gene therapy. Among 17 patients with Sanfilippo syndrome type A who received the therapy, cognition ...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
